|
2022 Journal Article BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian settingScolyer, Richard A., Atkinson, Victoria, Gyorki, David E., Lambie, Duncan, O'Toole, Sandra, Saw, Robyn P.M., Amanuel, Benhur, Angel, Christopher M., Button-Sloan, Alison E., Carlino, Matteo S., Ch'ng, Sydney, Colebatch, Andrew J., Daneshvar, Dariush, Pires da Silva, Inês, Dawson, Tamara, Ferguson, Peter M., Foster-Smith, Erwin, Fox, Stephen B., Gill, Anthony J., Gupta, Ruta, Henderson, Michael A., Hong, Angela M., Howle, Julie R., Jackett, Louise A., James, Craig, Lee, C. Soon, Lochhead, Alistair, Loh, Daphne, McArthur, Grant A. ... Long, Georgina V. (2022). BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 54 (1), 6-19. doi: 10.1016/j.pathol.2021.11.002 |
|
2022 Journal Article Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisGoldinger, Simone M., Buder-Bakhaya, Kristina, Lo, Serigne N., Forschner, Andrea, McKean, Meredith, Zimmer, Lisa, Khoo, Chloe, Dummer, Reinhard, Eroglu, Zeynep, Buchbinder, Elizabeth I., Ascierto, Paolo A., Gutzmer, Ralf, Rozeman, Elisa A., Hoeller, Christoph, Johnson, Douglas B., Gesierich, Anja, Kölblinger, Peter, Bennannoune, Naima, Cohen, Justine V., Kähler, Katharina C., Wilson, Melissa A., Cebon, Jonathan, Atkinson, Victoria, Smith, Jessica L., Michielin, Olivier, Long, Georgina V., Hassel, Jessica C., Weide, Benjamin, Haydu, Lauren E. ... Menzies, Alexander M. (2022). Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 162, 22-33. doi: 10.1016/j.ejca.2021.11.022 |
|
2021 Journal Article Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanomaEggermont, Alexander MM., Meshcheryakov, Andrey, Atkinson, Victoria, Blank, Christian U., Mandala, Mario, Long, Georgina V., Barrow, Catherine, Di Giacomo, Anna Maria, Fisher, Rosalie, Sandhu, Shahneen, Kudchadkar, Ragini, Ortiz Romero, Pablo Luis, Svane, Inge Marie, Larkin, James, Puig, Susana, Hersey, Peter, Quaglino, Pietro, Queirolo, Paola, Stroyakovskiy, Daniil, Bastholt, Lars, Mohr, Peter, Hernberg, Micaela, Chiarion-Sileni, Vanna, Strother, Matthew, Hauschild, Axel, Yamazaki, Naoya, van Akkooi, Alexander CJ., Lorigan, Paul, Krepler, Clemens ... Robert, Caroline (2021). Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European Journal of Cancer, 158, 156-168. doi: 10.1016/j.ejca.2021.09.023 |
|
2021 Journal Article Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedulesLong, Georgina V., Robert, Caroline, Butler, Marcus O., Couture, Felix, Carlino, Matteo S., O’Day, Steven, Atkinson, Victoria, Cebon, Jonathan S., Brown, Michael P., Dalle, Stephane, Hill, Andrew G., Gibney, Geoffrey T., McCune, Steven, Menzies, Alexander M., Niu, Cuizhen, Ibrahim, Nageatte, Moreno, Blanca Homet and Diab, Adi (2021). Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules. Clinical Cancer Research, 27 (19), 5280-5288. doi: 10.1158/1078-0432.CCR-21-0793 |
|
2021 Journal Article 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM studyAscierto, Paolo A., Dreno, Brigitte, Larkin, James, Ribas, Antoni, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Hsu, Jessie, Jones, Surai, Li, Haocheng, McKenna, Edward, Voulgari, Athina and McArthur, Grant A. (2021). 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study. Clinical Cancer Research, 27 (19), 5225-5235. doi: 10.1158/1078-0432.CCR-21-0809 |
|
2021 Journal Article Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survivalMandala, Mario, Larkin, James, Ascierto, Paolo Antonio, Del Vecchio, Michele, Gogas, Helen, Cowey, C. Lance, Arance, Ana, Dalle, Stéphane, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez, Ivan, Butler, Marcus O., Di Giacomo, Anna Maria, Lutzky, Jose, De La Cruz-Merino, Luis, Atkinson, Victoria, Arenberger, Petr, Hill, Andrew, Fecher, Leslie, Millward, Michael, Khushalani, Nikhil I., De Pril, Veerle, Lobo, Maurice and Weber, Jeffrey (2021). Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survival. Journal for ImmunoTherapy of Cancer, 9 (8) e003188, 1-9. doi: 10.1136/jitc-2021-003188 |
|
2021 Journal Article Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapyDearden, Helen, Au, Lewis, Wang, Daniel Y., Zimmer, Lisa, Eroglu, Zeynep, Smith, Jessica L., Cuvietto, Marcello, Khoo, Chloe, Atkinson, Victoria, Lo, Serigne, Long, Georgina V., Sandhu, Shahneen, Ascierto, Paolo A., Carlino, Matteo S., Johnson, Douglas B., Larkin, James and Menzies, Alexander M. (2021). Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 153, 168-178. doi: 10.1016/j.ejca.2021.04.045 |
|
2021 Journal Article Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapyHepner, Adriana, Atkinson, Victoria G., Larkin, James, Burrell, Rebecca A., Carlino, Matteo S., Johnson, Douglas B., Zimmer, Lisa, Tsai, Katy K., Klein, Oliver, Lo, Serigne N., Haydon, Andrew, Bhave, Prachi, Lyle, Megan, Pallan, Lalit, Pires da Silva, Ines, Gerard, Camille, Michielin, Olivier, Long, Georgina V. and Menzies, Alexander M. (2021). Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy. European Journal of Cancer, 153, 213-222. doi: 10.1016/j.ejca.2021.04.021 |
|
2021 Journal Article Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapySmithers, B. Mark, Saw, Robyn P. M., Gyorki, David E., Martin, Richard C. W., Atkinson, Victoria, Haydon, Andrew, Roberts‐Thomson, Rachel and Thompson, John F. (2021). Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. ANZ Journal of Surgery, 91 (S2), 3-13. doi: 10.1111/ans.17051 |
|
2021 Journal Article The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysisVersluis, Judith M., Hendriks, Anne M., Weppler, Alison M., Brown, Lauren J., de Joode, Karlijn, Suijkerbuijk, Karijn P.M., Zimmer, Lisa, Kapiteijn, Ellen W., Allayous, Clara, Johnson, Douglas B., Hepner, Adriana, Mangana, Joanna, Bhave, Prachi, Jansen, Yanina J.L., Trojaniello, Claudia, Atkinson, Victoria, Storey, Lucy, Lorigan, Paul, Ascierto, Paolo A., Neyns, Bart, Haydon, Andrew, Menzies, Alexander M., Long, Georgina V., Lebbe, Celeste, van der Veldt, Astrid A.M., Carlino, Matteo S., Sandhu, Shahneen, van Tinteren, Harm, de Vries, Elisabeth G.E. ... Jalving, Mathilde (2021). The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 151, 72-83. doi: 10.1016/j.ejca.2021.04.003 |
|
2021 Journal Article A retrospective analysis of dabrafenib and/or dabrafenib plus trametinib combination in patients with metastatic melanoma to characterize patients with long-term benefit in the individual patient program (Describe iii)Atkinson, Victoria G., Quaglino, Pietro, Aglietta, Massimo, Del Vecchio, Michele, Depenni, Roberta, Consoli, Francesca, Bafaloukos, Dimitrios, Ferrucci, Pier Francesco, Tulyte, Skaiste, Krajsová, Ivana, Ascierto, Paolo A., Gueli, Rossana, Arance, Ana, Gogas, Helen, Banerjee, Hiya, Saliba, Teddy, de Jong, Egbert and Neyns, Bart (2021). A retrospective analysis of dabrafenib and/or dabrafenib plus trametinib combination in patients with metastatic melanoma to characterize patients with long-term benefit in the individual patient program (Describe iii). Cancers, 13 (10) 2466, 1-13. doi: 10.3390/cancers13102466 |
|
2021 Journal Article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialBottomley, Andrew, Coens, Corneel, Mierzynska, Justyna, Blank, Christian U., Mandalà, Mario, Long, Georgina V., Atkinson, Victoria G., Dalle, Stéphane, Haydon, Andrew M., Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Puig, Susana, Ascierto, Paolo A., Larkin, James, Lorigan, Paul C., Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C. J., Krepler, Clemens, Ibrahim, Nageatte ... for the EORTC Melanoma Group (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 22 (5), 655-664. doi: 10.1016/S1470-2045(21)00081-4 |
|
2021 Journal Article Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patientsAoude, Lauren G., Wong, Bernadette, Bonazzi, Vanessa F, Brosda, Sandra, Walters, Shaun B., Koufariotis, Lambros T., Naeini, Marjan M., Pearson, John V, Oey, Harald, Patel, Kalpana, Bradford, Julia J., Bloxham, Conor J, Atkinson, Victoria, Law, Phillip, Strutton, Geoffrey, Bayley, Gerard, Yang, Samuel, Smithers, B. Mark, Waddell, Nicola, Miles, Kenneth and Barbour, Andrew P. (2021). Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients. Molecular Cancer Research, 19 (6) molcanres.1038.2020, 950-956. doi: 10.1158/1541-7786.mcr-20-1038 |
|
2021 Journal Article Human CD141+ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse modelLee, Yoke Seng, O'Brien, Liam J., Walpole, Carina M., Pearson, Frances E., Leal-Rojas, Ingrid M., Masterman, Kelly-Anne, Atkinson, Victoria, Barbour, Andrew and Radford, Kristen J. (2021). Human CD141+ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model. Journal for ImmunoTherapy of Cancer, 9 (3) e001963, 1-12. doi: 10.1136/jitc-2020-001963 |
|
2021 Journal Article Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council AustraliaHong, Angela M., Waldstein, Cora, Shivalingam, Brindha, Carlino, Matteo S., Atkinson, Victoria, Kefford, Richard F., McArthur, Grant A., Menzies, Alexander M., Thompson, John F. and Long, Georgina V. (2021). Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. European Journal of Cancer, 142, 10-17. doi: 10.1016/j.ejca.2020.10.013 |
|
2020 Journal Article KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanomaFerrucci, Pier Francesco, Di Giacomo, Anna Maria, Del Vecchio, Michele, Atkinson, Victoria, Schmidt, Henrik, Schachter, Jacob, Queirolo, Paola, Long, Georgina V., Stephens, Rosalie, Svane, Inge Marie, Lotem, Michal, Abu-Amna, Mahmoud, Gasal, Eduard, Ghori, Razi, Diede, Scott J., Croydon, Elizabeth S., Ribas, Antoni and Ascierto, Paolo Antonio (2020). KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. Journal for ImmunoTherapy of Cancer, 8 (2) e001806, 1-9. doi: 10.1136/jitc-2020-001806 |
|
2020 Journal Article Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanomaAtkinson, Victoria, Khattak, Adnan, Haydon, Andrew, Eastgate, Melissa, Roy, Amitesh, Prithviraj, Prashanth, Mueller, Christian, Brignone, Chrystelle and Triebel, Frederic (2020). Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. Journal for ImmunoTherapy of Cancer, 8 (2) e001681, 1-9. doi: 10.1136/jitc-2020-001681 |
|
2020 Journal Article Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trialAscierto, Paolo A., Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Maio, Michele, Middleton, Mark R., de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Lobo, Maurice, de Pril, Veerle, Loffredo, John, Larkin, James and Weber, Jeffrey (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 21 (11), 1465-1477. doi: 10.1016/S1470-2045(20)30494-0 |
|
2020 Journal Article Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patientsAoude, Lauren G., Bonazzi, Vanessa F., Brosda, Sandra, Patel, Kalpana, Koufariotis, Lambros T., Oey, Harald, Nones, Katia, Wood, Scott, Pearson, John V., Lonie, James M., Arneil, Melissa, Atkinson, Victoria, Smithers, B. Mark, Waddell, Nicola and Barbour, Andrew P. (2020). Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 10 (1) 17687, 17687. doi: 10.1038/s41598-020-74956-3 |
|
2020 Journal Article Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-iDummer, Reinhard, Lebbé, Celeste, Atkinson, Victoria, Mandalà, Mario, Nathan, Paul D., Arance, Ana, Richtig, Erika, Yamazaki, Naoya, Robert, Caroline, Schadendorf, Dirk, Tawbi, Hussein A., Ascierto, Paolo A., Ribas, Antoni, Flaherty, Keith T., Pakhle, Neha, Campbell, Catarina D., Gusenleitner, Daniel, Masood, Aisha, Brase, Jan C., Gasal, Eduard and Long, Georgina V. (2020). Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nature Medicine, 26 (10), 1557-1563. doi: 10.1038/s41591-020-1082-2 |
